UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 115

Sortiert nach

Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma

Journal of vascular and interventional radiology, 2013-03, Vol.24 (3), p.307-315

2013

Volltextzugriff (PDF)

Safety and Feasibility of Same-day Discharge of Patients with Unresectable Hepatocellular Carcinoma Treated with Doxorubicin Drug-eluting Bead Transcatheter Chemoembolization

Journal of vascular and interventional radiology, 2012-10, Vol.23 (10), p.1286-1293.e1

2012

Volltextzugriff (PDF)

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

Clinical cancer research, 2016-02, Vol.22 (4), p.847-857

2016

Volltextzugriff (PDF)

Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)

Journal of surgical oncology, 2010-05, Vol.101 (6), p.476-480

2010

Volltextzugriff (PDF)

Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study

Cardiovascular and interventional radiology, 2013-04, Vol.36 (2), p.440-448

2013

Volltextzugriff (PDF)

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial

Journal of clinical oncology, 2016-05, Vol.34 (13), p.1500-1509

2016

Volltextzugriff (PDF)

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer

Cancer chemotherapy and pharmacology, 2016-10, Vol.78 (4), p.815-824

2016

Volltextzugriff (PDF)

Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC

American journal of roentgenology (1976), 2014-12, Vol.203 (6), p.W706

2014

Volltextzugriff (PDF)

The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma

Journal of vascular and interventional radiology, 2010-08, Vol.21 (8), p.1197-1204

2010

Volltextzugriff (PDF)

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

Investigational new drugs, 2015-06, Vol.33 (3), p.652-663

2015

Volltextzugriff (PDF)

Chemotherapy in the Treatment of Metastatic Gastric Cancer: Is There a Global Standard?

Current treatment options in oncology, 2011-03, Vol.12 (1), p.96-106

2011

Volltextzugriff (PDF)

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203)

Cancer, 2018-02, Vol.124 (4), p.688-697

2018

Volltextzugriff (PDF)

Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection

Annals of surgical oncology, 2011-09, Vol.18 (9), p.2699-2705

2011

Volltextzugriff (PDF)

Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study

HPB (Oxford, England), 2010-04, Vol.12 (3), p.174-180

2010

Volltextzugriff (PDF)

Hypergastrinemia, type 1 gastric carcinoid tumors: diagnosis and management

Journal of clinical oncology, 2011-09, Vol.29 (25), p.e713-e715

2011

Volltextzugriff (PDF)

Clinically Relevant Biomarkers to Select Patients for Targeted Inhibitor Therapy after Resection of Hepatocellular Carcinoma

Annals of surgical oncology, 2011-11, Vol.18 (12), p.3384-3390, Article 3384

2011

Volltextzugriff (PDF)

A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS3159-TPS3159

2021

Volltextzugriff (PDF)

Through the looking glass: the evolution of erythropoiesis-stimulating agent use

Oncology (Williston Park, N.Y.), 2010-03, Vol.24 (3), p.269, 274-274

2010

Volltextzugriff (PDF)

An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS2677-TPS2677

2021

Volltextzugriff (PDF)

Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4114-4114

2021

Volltextzugriff (PDF)

Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4610-4610

2020

Volltextzugriff (PDF)

GBR1302: Effect of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.12053-12053

2018

Volltextzugriff (PDF)

Single-fraction image-guided extracranial radiosurgery for recurrent and metastatic abdominal and pelvic cancers: short-term local control, metabolic response, and toxicity

Journal of gastrointestinal oncology, 2010-09, Vol.1 (1), p.16-23

2010

Volltextzugriff (PDF)

Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS3132-TPS3132

2018

Volltextzugriff (PDF)

Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.TPS81-TPS81

2018

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(106)

Publikationsform

Artikel
(114)
Berichte
(1)

Sprache

Englisch
(115)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(58)
Science & Technology
(53)
Life Sciences & Biomedicine
(52)
Female
(46)
Middle Aged
(44)
Male
(43)
Oncology
(39)
Aged
(34)
Adult
(29)
Treatment Outcome
(22)
Aged, 80 And Over
(17)
Tumors
(17)
Neoplasm Staging
(15)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Medicine
(12)
Antineoplastic Agents - Therapeutic Use
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Medicine & Public Health
(11)
Neoplasms - Drug Therapy
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma

Safety and Feasibility of Same-day Discharge of Patients with Unresectable Hepatocellular Carcinoma Treated with Doxorubicin Drug-eluting Bead Transcatheter Chemoembolization

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)

Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer

Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC

The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

Chemotherapy in the Treatment of Metastatic Gastric Cancer: Is There a Global Standard?

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203)

Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection

Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study

Hypergastrinemia, type 1 gastric carcinoid tumors: diagnosis and management

Clinically Relevant Biomarkers to Select Patients for Targeted Inhibitor Therapy after Resection of Hepatocellular Carcinoma

A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations

Through the looking glass: the evolution of erythropoiesis-stimulating agent use

An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors

Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs)

Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs)

GBR1302: Effect of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers

Single-fraction image-guided extracranial radiosurgery for recurrent and metastatic abdominal and pelvic cancers: short-term local control, metabolic response, and toxicity

Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma

Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma

Suchergebnisse filtern